Current Literature
In Clinical Science

Neonatal Seizures Due to Hypoxic-Ischemic Encephalopathy: Should We Care?

Clinical Seizures in Neonatal Hypoxic-Ischemic Encephalopathy Have No Independent Impact on Neurodevelopmental Outcome: Secondary Analyses of Data From the Neonatal Research Network Hypothermia Trial.


It remains controversial as to whether neonatal seizures have additional direct effects on the developing brain separate from the severity of the underlying encephalopathy. Using data collected from infants diagnosed with hypoxic-ischemic encephalopathy, and who were enrolled in an National Institute of Child Health and Human Development trial of hypothermia, we analyzed associations between neonatal clinical seizures and outcomes at 18 months of age. Of the 208 infants enrolled, 102 received whole body hypothermia and 106 were controls. Clinical seizures were generally noted during the first 4 days of life and rarely afterward. When adjustment was made for study treatment and severity of encephalopathy, seizures were not associated with death, or moderate or severe disability, or lower Bayley Mental Development Index scores at 18 months of life. Among infants diagnosed with hypoxic-ischemic encephalopathy, the mortality and morbidity often attributed to neonatal seizures can be better explained by the underlying severity of encephalopathy.

Commentary

Most child neurologists approach the hospital neonatal intensive care unit (NICU) with fear and trepidation. The most frequent consultation, which leads to this sense of unease, is a newborn term infant with hypoxic-ischemic encephalopathy (HIE) who has now just started to develop seizures. Unlike seizures in older children, to some extent, for whom some evidence-based guidelines do exist, neonatal seizures are often beyond our comfort zone.

Why? For one, seizures are common with HIE and can be extremely subtle to the extent of being not clinically observable in nearly half of neonates (1, 2). Additionally, the relatively new technology of amplitude-integrated EEG (aEEG) has emerged in the NICU as standard-of-care, in which long epochs of information derived from limited electrode channels, is typically interpreted by neonatologists (3). The true value and benefit of this technology is unclear. Last, as shown both by the authors of this paper in a previous article (4) and by a recent Cochrane group analysis (5), commonly used anticonvulsants for neonates such as phenobarbital and phenytoin, are unproven at best and harmful at worst.

Certainly it is difficult for a neonatologist, nurse, parent, or neurologist to stand at the incubator and watch a neonate convulse. However, if our treatments do not work, and the seizures are not having any true impact on the child’s long-term outcomes, then perhaps watching is the appropriate intervention. We know from the infantile spasms literature that the underlying etiology trumps the success of treatment in regard to long-term development (6). In many cases of epilepsy, the seizures are mostly a symptom of an abnormal brain structure or genetic etiology, as opposed to a true epileptic encephalopathy. Neonates who are in the intensive care unit with HIE are under close, intense, respiratory and hemodynamic supervision and protection; a brief seizure will likely have minimal systemic impact.

It is into the fray of this exceptional equipoise that this research by Kwon and colleagues from the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network is now available. Just 4 years ago in this same journal (Journal of Child Neurology), the same first two authors evaluated 146 infants with seizures, by a phone survey, and determined that phenobarbital prophylaxis did not improve neurologic outcomes up to 12 years (4). They continue to question the status quo by addressing in this current study whether clinical (not solely electrographic) seizures in neonates with HIE have a true independent direct effect on development, as measured by the Bayley Mental Development Index (MDI) at 18 months of age. Data from the
Neonatal Research Network’s trial of therapeutic hypothermia had suggested that seizures at enrollment were associated with a poor outcome (7). The authors attempted to determine if that finding was still true, when examining for the entire hospital course of these neonates, and “whether the seizures themselves have an independent impact on the immature neonatal brain and are responsible for additional damage.”

Their findings were that with univariate analysis there was both double the risk of seizures in children with severe HIE (44% vs 21%, \( p < 0.001 \)) and an MDI score less than 70 (40% vs 20%, \( p = 0.02 \)). When statistically controlling for both the effects of hypothermia and severe HIE, however, the effects of neonatal seizures no longer had a significant influence (odds ratio 1.93 (0.83–4.48), \( p = 0.13 \)). Based on this, Kwon and colleagues concluded that “the presence of neonatal seizures cannot cause added harm in the setting of neonatal encephalopathy.”

The authors thoroughly acknowledged the limitations of this study in a paragraph that was approximately half the length of the entire discussion section. They appropriately point out that clinical seizures are subtle, but that EEG was not required in the study protocol. In addition, a “high percentage” of infants received anticonvulsant drugs. Secondary etiologies for seizures other than HIE were not accounted for, and MRI was not available for analysis.

These limitations and more were pointed out in an editorial in the same journal one issue later by Glass, Ferriero, and Miller, three authors very familiar with neonatal seizures (8). These authors had in fact published results 2 years prior, reporting that seizures were independently associated with poor outcome in HIE (9). Perhaps part of their impetus for writing this editorial was a single word in the study, which they italicized in their correspondence, “cannot cause added harm…” (9).

Glass and colleagues went on to highlight that there is a difference between statistical and clinical significance: an odds ratio of 1.93 might not be statistically significant, but that represents a doubling (or even higher) of the risk of developmental disability. In addition, they pointed out that transient seizures at enrollment, as specified by this current study, may be very different in impact on a neonate than ongoing, persistent, and perhaps even difficult-to-control seizures. They finally asked for more information regarding the influence of hypothermia on seizures, for which the authors then provided further data demonstrating no effect on the outcome (10).

So where do we go from here? As mentioned by the authors of this article and the correspondence, a prospective study utilizing continuous video-EEG is one step, albeit an expensive one. In addition, the population would need to be large, multicenter, and homogenous in etiology. Last, and perhaps most important, neonatologists and child neurologists alike need better treatments, especially if we do find that seizures in fact matter and are independently detrimental. Then and only then is this debate truly relevant: if our hands are tied by ineffective or harmful treatments, then matter or not, neonates with HIE are in trouble despite our best assistance.

by Eric Kossoff, MD

References
Disclosure of Potential Conflicts of Interest

Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. **Identifying information.**
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. **The work under consideration for publication.**
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. **Relevant financial activities outside the submitted work.**
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. **Other relationships**
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
## Section #1 Identifying Information

1. Today’s Date: ___1/22/11_____________________________

2. First Name __Eric______________ Last Name __Kossoff___________ Degree __MD_______

3. Are you the Main Assigned Author? _X___ Yes _____ No

   If no, enter your name as co-author ________________________________________________________

   Manuscript/Article Title: ___ THE FAT IS IN THE FIRE: KETOGENIC DIET FOR REFRACTORY
   STATUS EPILEPTICUS

4. Journal Issue you are submitting for: _Epilepsy Currents_____________________________________

## Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted
work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical
analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship
just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td></td>
<td>X</td>
<td>Nutricia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td></td>
<td>X</td>
<td>Atkins Nutritionals</td>
<td>Scientific Advisory Board</td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.
** Use this section to provide any needed explanation.
### Section #3 Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>service on speakers bureaus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation.</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>educational presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>unrelated to activities listed.**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>disclosure)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

### Section #4 Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

_X_ No other relationships/conditions/circumstances that present a potential conflict of interest.

___ Yes, the following relationships/conditions/circumstances are present:

____________________________________________________________________________________________
____________________________________________________________________________________________
____________________________________________________________________________________________

Thank you for your assistance.

*Epilepsy Currents* Editorial Board